Table 1.

Characteristics of patients at inclusion in the study [n = 53]

Characteristic	Median [interquartile range] or percentage and range
Female	21 [40]
Age at diagnosis	32.29 [22.90–41.42]
Age at inclusion	46.41 [31.90–54.96]
Disease duration [years]	7.19 [2.85–19.33]
Disease extent at diagnosis
▪E2 Left sided	31 [58]
▪E3 Extensive	22 [42]
Concomitant treatmentsa
▪Steroids	9 [17]
▪Immunosuppressants	1 [2]
▪Biologic therapyb	12 [23]
Smoking
▪Past	14 [26]
▪Active	3 [6]
Partial Mayo score [PMS]	2 [0–5]
PMS > 2	21 [40]
CRP [mg/L]	5.0 [1.75–8.30]
Calprotectin [µg/g]	422.5 [99.0–1414.0]
Mayo endoscopic sub-score
▪0	13 [24]
▪1	9 [17]
▪2	12 [23]
▪3	19 [36]
Disease extent at colonoscopy at inclusion
▪E2 Left-sided	30 [56]
▪E3 Extensive	10 [19]

CRP, C-reactive protein.

** All patients took mesalazine; * 8 patients were given infliximab, 4 vedolizumab